Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Nektar Therapeutics (NKTR)

Nektar Therapeutics (NKTR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Insider Sale: Chief R&D Officer of $NKTR (NKTR) Sells 7,785 Shares

Jonathan Zalevsky, the Chief R&D Officer of $NKTR ($NKTR), sold 7,785 shares of the company on 11-19-2024. We received data on the trade from a recent SEC filing. This was a sale of approximately 3.1%...

NKTR : 1.0050 (+0.50%)
Nektar: Q3 Earnings Snapshot

Nektar: Q3 Earnings Snapshot

NKTR : 1.0050 (+0.50%)
Wall Street is Overlooking This Penny Stock, Says Analyst

This penny stock could surge up to 200%, according to one bull, who has high hopes for a pipeline drug ahead of trial data due out in 2025.

AAPL : 229.49 (+0.21%)
AMZN : 198.39 (-2.21%)
NKTR : 1.0050 (+0.50%)
Nektar: Q2 Earnings Snapshot

Nektar: Q2 Earnings Snapshot

NKTR : 1.0050 (+0.50%)
Nektar Presents New Responder Data for Rezpegaldesleukin, a First-in-Class Selective Regulatory T-cell Therapy, in Late-Breaking News Oral Presentation at 2023 EADV Congress

/PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) today announced new data for rezpegaldesleukin (REZPEG), a first-in-class selective regulatory T-cell (Treg)...

NKTR : 1.0050 (+0.50%)
Nektar Therapeutics Announces Two Abstracts Accepted at EADV Congress 2023 for Rezpegaldesleukin, a First-in-Class Selective Regulatory T-cell Therapy

/PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) announced today that it will have two presentations for rezpegaldesleukin (REZPEG), a first-in-class...

NKTR : 1.0050 (+0.50%)
Nektar Therapeutics Announces New Clinical Study Collaboration with Cellular Biomedicine Group Inc. to Evaluate NKTR-255 in Combination with C-TIL051 in Advanced Non-Small Cell Lung Cancer

/PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) announced today that it has entered into a new clinical study collaboration with Cellular Biomedicine Group...

NKTR : 1.0050 (+0.50%)
Nektar Therapeutics to Host Virtual Investor & Analyst Event with Dermatology Experts on September 13th

/PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced that it will host a virtual investor and analyst event on Wednesday, September 13, 2023 at...

NKTR : 1.0050 (+0.50%)
Nektar Therapeutics Reports Second Quarter 2023 Financial Results

/PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the second quarter ended June 30, 2023. Cash and investments in...

NKTR : 1.0050 (+0.50%)
Nektar Announces Promising New and Corrected Rezpegaldesleukin Efficacy Data Which Were Previously Reported in 2022 and Incorrectly Calculated by Former Collaborator Eli Lilly & Company

/PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced that efficacy data previously generated by Eli Lilly & Company for rezpegaldesleukin...

NKTR : 1.0050 (+0.50%)

Barchart Exclusives

Are Cattle Prices Heading for Record Highs in 2025?
Live and cattle feeder futures prices have risen since the 2020 pandemic-inspired lows. After reaching record highs in 2024, cattle futures are consolidating, and new highs could be on the horizon in 2025. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar